Sign Up to like & get
recommendations!
1
Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2020-99
Abstract: A phase II trial shows that a chemotherapy-free regimen of dasatinib and blinatumomab produces molecular responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. The study found that 60% of patients had molecular responses after…
read more here.
Keywords:
molecular responses;
combo may;
obviate chemotherapy;
may obviate ... See more keywords